Relationship between a perioperative intravenous fluid administration strategy and acute kidney injury following off-pump coronary artery bypass surgery: an observational study by Ji-Yeon Kim et al.
RESEARCH Open Access
Relationship between a perioperative
intravenous fluid administration strategy and
acute kidney injury following off-pump coronary
artery bypass surgery: an observational study
Ji-Yeon Kim1, Kyoung-Woon Joung1, Kyung-Mi Kim1, Min-Ju Kim2, Joon-Bum Kim3, Sung-Ho Jung3,
Eun-Ho Lee1* and In-Cheol Choi1
Abstract
Introduction: Saline-based and hydroxyethyl starch solutions are associated with increased risk of renal
dysfunction. In the present study, we tested the hypothesis that balanced solutions and a limited volume of
hydroxyethyl starch solution (renal protective fluid management [RPF] strategy) would decrease the incidence of
postoperative acute kidney injury (AKI) and improve clinical outcomes in patients undergoing off-pump coronary
artery bypass graft surgery (OPCAB).
Methods: We investigated 783 patients who underwent elective OPCAB. All patients who underwent OPCAB
between 1 January 2010 and 4 July 2012 formed the control group and were given intravenous fluids with
saline-based solutions and unlimited volumes of colloid solutions. All patients who underwent OPCAB between
5 July 2012 and 31 December 2013 formed the RPF group and were given intravenous fluids with RPF. The primary
outcome was the incidence of postoperative AKI. Secondary outcomes included the incidence of severe AKI,
requirement for renal replacement therapy, renal outcome at the time of discharge, and other clinical outcomes.
Results: Postoperative AKI occurred in 33 patients (14.4 %) in the RPF group compared with 210 patients (37.9 %)
in the control group (P < 0.001). The incidences of severe AKI and persistent AKI after OPCAB were significantly
lower, and the postoperative extubation time and duration of hospital stay were significantly shorter, in patients in
the RPF group than in those in the control group. After adjustment by multivariate regression analyses and inverse
probability of treatment weighting adjustment, the RPF group was independently associated with a lower
incidence of postoperative AKI, severe AKI, and persistent AKI and a shorter postoperative extubation time and
duration of hospital stay.
Conclusions: The RPF strategy is associated with a significantly decreased incidence of postoperative, severe, and
persistent AKI in patients undergoing OPCAB, although residual confounding may be present.
Introduction
Acute kidney injury (AKI) is a well-known, common,
and serious complication of coronary artery bypass graft
surgery. AKI is associated with a prolonged hospital stay
and increased morbidity and mortality, even for patients
who do not progress to renal failure [1–3]. In clinical
studies, the incidence of AKI is approximately 18 % and
the incidence of new-onset renal failure requiring renal
replacement therapy (RRT) is approximately 2–6 % after
cardiac surgery [4, 5]. Because there are no effective
treatments for AKI, the current focus of clinicians is
on prevention and risk factor management of this
condition.
Perioperative fluid management can affect postopera-
tive renal function. Normal saline solution is the most
commonly used intravenous solution in perioperative
* Correspondence: leho@naver.com
1Department of Anesthesiology and Pain Medicine, Asan Medical Center,
University of Ulsan College of Medicine, 388-1, Pungnap 2-dong, Songpa-gu,
Seoul 138-736, Korea
Full list of author information is available at the end of the article
© 2015 Kim et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kim et al. Critical Care  (2015) 19:350 
DOI 10.1186/s13054-015-1065-8
fluid management [6]. However, recent clinical studies
have shown that excessively large volumes of saline-
based solutions may cause hyperchloremic acidosis,
which can lead to decreased renal blood flow and poor
clinical outcomes [7–11]. In a previous human study,
the intravenous infusion of normal saline reduced renal
blood flow velocity and renal cortical tissue perfusion
[12]. In contrast, other studies have shown that balanced
crystalloid and colloid solutions can prevent the devel-
opment of hyperchloremic metabolic acidosis and in-
crease the mean level of renal cortical tissue perfusion
compared with saline-based solutions [13–15]. The use
of balanced solutions has also been associated with a re-
duced risk of renal dysfunction in surgical and critically
ill patients [16, 17]. Thus, balanced salt solutions con-
taining physiologic levels of chloride and buffer may
offer clinical benefits over saline-based solutions.
Hydroxyethyl starch (HES) solution is one of the most
commonly used synthetic colloids for correcting hypo-
volemia during surgery. Compared with crystalloid solu-
tions, colloid solutions are generally considered to be
more effective volume expanders because of their
smaller volume of distribution [18]. However, several re-
cent reports have suggested that the administration of
HES solution is associated with an increased risk of renal
dysfunction, coagulation abnormality, and mortality
[19–21]. These adverse effects of HES seem to in-
crease with higher doses [20, 22]. Thus, given the safety is-
sues of saline-based and HES solutions for renal function,
perioperative fluid management using balanced solutions
and limited volumes of HES solution (renal protective
fluid management [RPF] strategy) may have beneficial
effects on renal function and other clinical outcomes.
The purpose of this study was to investigate the effect
of an RPF strategy on the postoperative renal function
and clinical outcomes in patients who underwent off-
pump coronary artery bypass graft surgery (OPCAB).
We hypothesized that an RPF strategy would be associ-
ated with a decreased incidence of postoperative AKI
and improved clinical outcomes.
Material and methods
Patient population
This retrospective observational study was conducted
with all patients aged 20 years or older who underwent
OPCAB at Asan Medical Center, Seoul, Korea, between
1 January 2010 and 31 December 2013. All clinical data
of the study patients, including demographics, laboratory
data, and perioperative fluids, were acquired from the
Asan Medical Center Coronary Artery Bypass Surgery
and Anesthesia Database and by a retrospective review
of the computerized patient record system (Asan Medical
Center Information System Electronic Medical Record)
[23]. Exclusion criteria included emergency or urgent
surgery (n = 37), preexisting end-stage kidney disease re-
quiring dialysis (n = 32), prior nephrectomy or kidney
transplantation (n = 4), and any concomitant cardiac sur-
gery besides OPCAB (n = 2). Two patients in the RPF
group receiving saline-based solution for hyponatremia
were also excluded. This study was approved by the
local ethics committee (Asan Medical Center Institutional
Review Board, Seoul, Republic of Korea, protocol number
2014-0697) and performed in accordance with Strength-
ening the Reporting of Observational Studies in Epidemi-
ology guidelines [24]. The board waived the need for
informed consent.
This retrospective study included two cohorts that were
defined on the basis of the type and amount of fluid re-
ceived during surgery and in the immediate postoperative
period (i.e., within 48 h after surgery). On 5 July 2012, we
changed the perioperative fluid management strategy from
a saline-based solution and unlimited amounts of HES so-
lution to a balanced solution and limited amounts of HES
solution (RPF strategy). We defined the control group as
patients who underwent OPCAB during the control
period (between 1 January 2010 and 4 July 2012) and the
RPF group as patients who underwent OPCAB during the
renal protection period (between 5 July 2012 and 31
December 2013). This control period was chosen because
surgical and perioperative care were similar, except for the
perioperative fluid management strategy.
For fluid management, all patients in the control group
were given intravenous fluids with a saline-based solution
and unlimited amounts of colloid solution during surgery
and in the immediate postoperative period. The saline-
based solution comprised chloride-rich fluids and in-
cluded 0.9 % saline (chloride concentration 150 mmol/L;
JW Pharmaceutical, Seoul, Korea) and 6 % HES 130/0.4
(chloride concentration 154 mmol/L, Voluven®; Fresenius
Kabi, Bad Homburg, Germany). In contrast, all patients of
the RPF group were given intravenous fluids with a bal-
anced solution during surgery and a limited amount of
colloid solution during surgery and in the immediate
postoperative period (cumulative amount <30 ml/kg body
weight). The balanced solution comprised chloride-
restrictive fluids and included Plasma Solution-A (chloride
concentration 98 mmol/L; CJ HealthCare, Seoul, Korea)
and 6 % HES 130/0.4 (chloride concentration 110 mmol/L,
Volulyte®; Fresenius Kabi). In the immediate postoperative
period, the patients in the RPF group received balanced
colloid and saline-based crystalloid (0.9 % saline) solutions.
Intraoperative and postoperative management
Our perioperative management strategies have been
described in detail previously [23]. Briefly, anesthesia
was maintained with a continuous infusion of propofol
and remifentanil using a target-controlled infusion pump
(Orchestra Base Primea; Fresenius Vial, Brézins, France).
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To maintain cardiac preload, patients were administered
intravenous fluids, and those with a hemoglobin concen-
tration <8 g/dl were administered packed red blood cells
(pRBCs). Despite optimization of the circulating blood
volume, patients with low blood pressure or cardiac out-
put received agents such as phenylephrine, dopamine, or
norepinephrine. A cell salvage device (autoLog Auto-
transfusion System; Medtronic, Minneapolis, MN, USA)
was used in all patients, and salvaged blood was rein-
fused before the end of surgery. All surgical procedures
were conducted by three cardiac surgeons highly experi-
enced in OPCAB. Median sternotomy was performed in
all patients, and complete myocardial revascularization
with either arterial or saphenous vein grafts was the
primary surgical goal for each patient. At the end of sur-
gery, patients were transferred to the intensive care unit
(ICU). Patients were extubated when their hemodynamics
were stable, after which they breathed spontaneously and
achieved adequate blood gases. Fluid management con-
sisted of infusion of 5 % dextrose with additional normal
saline or colloid solution to maintain normovolemia.
pRBCs were transfused to maintain hemoglobin >9 g/dl,
and fresh frozen plasma, platelet concentrate, or cryo-
precipitate was transfused to correct blood coagulation.
Patients were discharged from the ICU to the general
ward when their clinical status was stable and further ICU
monitoring and care were not required. Perioperative
fluid management is further described in Additional
file 1: Supplementary methods.
Definition of outcomes
The primary outcome of this study was the incidence of
postoperative AKI. The occurrence of AKI after surgery
was determined according to Kidney Disease: Improving
Global Outcomes (KDIGO) criteria (increase in serum
creatinine by ≥0.3 mg/dl within 48 h of surgery or in-
crease in serum creatinine to ≥1.5 times baseline within
7 days of surgery) [25]. The diagnosis of AKI was based
on the highest serum creatinine concentration measured
during the first 7 days after surgery compared with the
baseline serum creatinine concentration, defined as the
last concentration measured before surgery. Urine out-
put was not used, because the data were recorded incon-
sistently among the study patients and may have been
affected by diuretic use. AKI was also staged for severity
according to the following KDIGO criteria:
 Stage 1: increase in serum creatinine by ≥0.3 mg/dl
or 1.5 to 1.9 times baseline
 Stage 2: increase in serum creatinine 2.0 to 2.9 times
baseline
 Stage 3: increase in serum creatinine 3.0 or
more times baseline or an increase in serum
creatinine ≥4.0 mg/dl or initiation of RRT
Secondary outcomes were the incidence of severe AKI
(KDIGO stage 2 or higher), requirement for RRT, renal
outcome at the time of discharge, time to extubation
following surgery, lengths of ICU and hospital stay after
surgery, and death due to any cause occurring during
the initial hospital stay after surgery. RRT was defined as
any use of intermittent hemodialysis or continuous veno-
venous hemodiafiltration. Renal outcome at the time of
discharge was determined by comparing the discharge
serum creatinine level to the baseline serum creatinine.
Complete renal recovery was defined as a discharge serum
creatinine level <1.5 times baseline. Persistent AKI was de-
fined as a discharge serum creatinine >1.5 times baseline
or a need for RRT at discharge. Serum chloride levels were
measured preoperatively and upon arrival at the ICU.
The maximal cardiovascular component of the Se-
quential Organ Failure Assessment (SOFA-C) score
observed within the first 24 h after surgery was used
to evaluate postoperative cardiovascular function [26].
Statistical analysis
Descriptive statistics are reported as numbers and
percentages for categorical variables and means with
standard deviations for continuous variables. To assess
associations between patients’ characteristics and clinical
factors, univariate analyses were performed using χ2 or
Fisher’s exact test for categorical variables and Student’s
t test or the Mann–Whitney rank-sum test for conti-
nuous variables. Univariate and multivariable logistic
regression analyses were conducted to investigate the ef-
fect of an RPF strategy on postoperative AKI. All vari-
ables in Table 1 were tested, and variables with P < 0.1 in
univariate analyses (i.e., age, diabetes mellitus, hyperten-
sion, congestive heart failure, cerebrovascular disease,
preoperative estimated glomerular filtration rate <60 ml/
min/1.73 m2, logistic EuroSCORE [European System for
Cardiac Operative Risk Evaluation], preoperative hema-
tocrit, serum creatinine, albumin, uric acid, coronary angi-
ography <5 days, use of angiotensin-converting enzyme
inhibitor or angiotensin receptor blocker, use of diuretics,
anesthesia time) were entered into the multivariable logis-
tic model. Because perioperative blood product transfu-
sion and maximal SOFA-C score could be associated with
the postoperative AKI (i.e., potential confounders), we also
adjusted these variables in the main analyses. The final
models were determined by backward elimination proce-
dures with P < 0.05 as model retention criteria.
To reduce the impact of treatment selection bias and
potential confounding in an observational study, we also
performed rigorous adjustment for significant differences
in patient characteristics by use of a weighted logistic
regression model or a weighted linear regression model
using inverse probability of treatment weighting (IPTW).
With that technique, weights for patients in the RPF
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Table 1 Baseline and intraoperative characteristics
Variable Control group RPF group P value
Number of patients 554 229
Demographics
Age (yr) 63.9 ± 9.2 63.7 ± 9.4 0.852
Male sex 431 (77.8) 179 (78.2) 0.910
Clinical characteristics
Body mass index (kg/m2) 24.6 ± 3.1 24.6 ± 3.1 0.706
EuroSCORE (logistic) 3.6 ± 3.6 3.5 ± 5.1 0.050
Medical history
Diabetes mellitus 263 (47.5) 99 (43.2) 0.279
Hypertension 365 (65.9) 151 (65.9) 0.988
Smoker, current 174 (31.4) 58 (25.3) 0.090
Previous myocardial infarction 69 (12.5) 43 (18.8) 0.022
Congestive heart failure 16 (2.9) 12 (5.2) 0.107
s/p PTAC c stent 108 (19.5) 50 (21.8) 0.458
Cerebrovascular disease 145 (26.2) 44 (19.2) 0.038
Peripheral vascular disease 61 (11.0) 18 (7.9) 0.183
eGFR <60 ml/min/1.73 m2 81 (14.6) 35 (15.3) 0.812
Liver disease 25 (4.5) 2 (0.9) 0.011
Left main coronary artery disease 128 (23.1) 48 (21.0) 0.513
Coronary angiography <5 days 177 (31.9) 78 (34.1) 0.566
Laboratory data
Hematocrit (%) 38.5 ± 4.8 38.7 ± 5.4 0.710
Creatinine (mg/dl) 1.0 ± 0.4 1.0 ± 0.4 0.469
Total bilirubin (mg/dl) 0.8 ± 0.3 0.6 ± 0.3 <0.001
Albumin (g/dl) 3.9 ± 0.4 3.8 ± 0.5 0.105
Uric acid (mg/dl) 5.5 ± 1.5 5.6 ± 1.6 0.745
Left ventricular ejection fraction (%) 56.4 ± 10.0 57.1 ± 10.5 0.165
Medication
ACEI or ARB 249 (44.9) 105 (45.9) 0.817
β-blocker 381 (68.8) 152 (66.4) 0.513
Calcium channel blocker 416 (75.1) 159 (69.4) 0.103
Insulin 127 (22.9) 43 (18.8) 0.200
Oral hypoglycemic agent 209 (37.7) 85 (37.1) 0.873
Statin 431 (77.8) 202 (88.2) 0.001
Aspirin 418 (75.5) 201 (87.8) <0.001
Clopidogrel 298 (53.8) 146 (63.8) 0.010
Diuretics 104 (18.8) 43 (18.8) 0.999
Intraoperative data
Anesthesia time (min) 295 [267–335] 300 [275–340] 0.151
Operation time (min) 228 [200–267] 230 [200–262] 0.882
Grafts per patient (n) 3 [2–4] 3 [2–3] 0.015
RPF renal protective fluid management, EuroSCORE European System for Cardiac Operative Risk Evaluation, PTCA c stent percutaneous transluminal catheter
angioplasty with stent insertion, eGFR estimated glomerular filtration rate, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker
Data are expressed as number of patients (%), mean ± standard deviation, or median [interquartile range]
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group were the inverse of (1 − propensity score), and
weights for patients in the control group were the inverse
of the propensity score. The propensity scores were esti-
mated by multiple logistic regression analysis. To create
the propensity score, all prespecified covariates were in-
cluded in the full non-parsimonious models for the RPF
group versus the control group. A list of all variables is
provided in Additional file 1: eTable S1.
In addition, univariate and multivariate analyses (step-
wise selection method for the linear regression model or
backward elimination method for the logistic regression
model) were performed to determine which of the inde-
pendent variables were related to the secondary outcome
variables. In sensitivity analyses, we explored the effects
of additional adjustment for potential confounding vari-
ables on the estimated relationship between RPF strategy
and AKI. We also examined the effect of an RPF strategy
on postoperative AKI in the subgroup with perioperative
cumulative amounts of HES <30 ml/kg. Furthermore, we
examined the effect of perioperative cumulative amounts
of HES as a continuous variable on postoperative AKI.
Multivariate logistic or linear regression analyses were
used to assess the odds ratios (ORs) or β coefficients
with 95 % confidence intervals (CIs) of the relationships
between the RPF strategy and outcome variables. The
discrimination and calibration abilities of each propen-
sity score model were assessed by using the C statistic
and the Hosmer–Lemeshow statistic, respectively.
All reported P values are two-sided, and values of
P < 0.05 were considered to indicate statistical signifi-
cance. SAS software version 9.3 (SAS Institute, Cary, NC,
USA) was used for the statistical analysis.
Results
A total of 860 patients underwent OPCAB between 1
January 2010 and 31 December 2013. After the exclusion
of patients who met any of the exclusion criteria, 783
patients remained. Of these, there were 554 patients in
the control group and 229 in the RPF group (Fig. 1).
The baseline and operative characteristics of the study
groups are shown in Table 1. There were minor differ-
ences between the two groups. Compared with patients
in the RPF group, patients in the control group were
more likely to have histories of cerebrovascular disease
and liver disease. Patients in the control group were also
less likely to be receiving statins. Patients in the RPF
group received more crystalloid solution (34.3 [25.3–
44.5] ml/kg vs. 24.2 [18.4–31.5] ml/kg; P < 0.001) and
less colloid solution (14.4 [10.1–17.4] ml/kg vs. 18.5
[14.8–22.4] ml/kg; P < 0.001) during surgery than the
control group (Table 2). The cumulative amount of
colloid received during surgery and in the immediate
postoperative period was lower in the RPF group than
in the control group (16.0 [11.0–20.1] ml/kg vs. 35.0
[27.1–44.7] ml/kg; P < 0.001). During surgery and in
the immediate postoperative period, patients in the
Fig. 1 Study flowchart. RPF renal protective fluid management, KT kidney transplantation
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RPF group received fewer units of pRBCs (2.1 ± 1.9 vs.
2.8 ± 2.6; P < 0.001), and fewer patients in the RPF group
received fresh frozen plasma (33.6 % vs. 47.8 %; P < 0.001)
and platelet concentrate (14.8 % vs. 32.7 %; P < 0.001) than
those in the control group. Postoperative percentage body
weight gain was higher in the RPF group than in the con-
trol group (2.6 ± 2.1 % vs. 1.9 ± 2.2 %; P < 0.001).
The preoperative serum chloride level was similar
between the two groups (104.4 ± 3.1 mmol/L in the RPF
group vs. 104.9 ± 3.2 mmol/L in the control group; P =
0.187), but the immediate postoperative serum chloride
level was significantly lower in the RPF group than in
the control group (108.8 ± 4.3 mmol/L vs. 113.3 ±
3.6 mmol/L, respectively; P < 0.001) (Fig. 2).
Postoperative outcomes are shown in Table 3. The
postoperative extubation time and the duration of hos-
pital stay were significantly shorter in the RPF group
than in the control group, but there was no significant
difference between the two groups in the duration of
ICU stay or in-hospital mortality. A total of 243 patients
(31.0 %) developed AKI after OPCAB surgery. Of these,
192 patients developed AKI within the first 48 h after
surgery (Additional file 1: eTable S2). Postoperative AKI
occurred in 33 patients (14.4 %) in the RPF group
compared with 210 patients (37.9 %) in the control
group (P < 0.001). The incidence of severe AKI and per-
sistent AKI after OPCAB was also lower in RPF group
patients than in the control group (3.5 % vs. 11.4 %
[P < 0.001] and 1.7 % vs. 10.7 % [P < 0.001], respectively).
The incidence of RRT was lower in the RPF group, but
there was no significant difference between the two
groups in this regard.
After adjustment by multivariate regression analyses
and IPTW, the RPF group was independently associated
with a lower incidence of postoperative AKI (OR 0.31
[95 % CI 0.19–0.50], P < 0.001 after multivariate logis-
tic analysis; OR 0.23 [95 % CI 0.15–0.35], P < 0.001
after IPTW), severe AKI (OR 0.30 [95 % CI 0.12–0.75],
P = 0.009 after multivariate logistic analysis; OR 0.12 [95 %
CI 0.04–0.36], P < 0.001 after IPTW), and persistent AKI
(OR 0.20 [95 % CI 0.06–0.67], P = 0.008 after multivariate
logistic analysis; OR 0.20 [95 % CI 0.08–0.52], P = 0.001
after IPTW) (Table 4) (Additional file 1: eTables S3, S4,
and S5). The RPF group was also significantly asso-
ciated with a shorter postoperative extubation time
(β −0.28 [95 % CI −0.37 to −0.19], P < 0.001 after
multivariate analysis; β −0.33 [95 % CI −0.42 to −0.23],
P < 0.001 after IPTW) and a shorter duration of hos-
pital stay (β −0.11 [95 % CI −0.17 to −0.05], P < 0.001
after multivariate analysis; β −0.18 [95 % CI −0.24
to −0.11], P < 0.001 after IPTW) (Additional file 1: eTables
S6 and S7).
A significant relationship between RPF strategies and
postoperative AKI was consistent with the results of
Table 2 Perioperative fluid administration in the study groups
Variable Control group RPF group P value
Number of patients 554 229
Intraoperative data
Crystalloid (L) 1.6 [1.2–2.0] 2.2 [1.8–2.8] <0.001
Crystalloid per weight (ml/kg) 24.2 [18.4–31.5] 34.3 [25.3–44.5] <0.001
Colloid (L) 1.2 [1.0–1.5] 1.0 [0.6–1.0] <0.001
Colloid per weight (ml/kg) 18.5 [14.8–22.4] 14.4 [10.1–17.4] <0.001
Colloid-to-crystalloid volume ratio 0.8 [0.6–1.0] 0.4 [0.3–0.6] <0.001
Cell salvage blood (ml) 237.4 ± 328.0 138.7 ± 208.1 <0.001
Data in intensive care unit
Colloid (L) 1.0 [0.5–1.5] 0 [0–0.2] <0.001
Colloid per weight (ml/kg) 16.1 [8.5–24.8] 0 [0–3.1] <0.001
Cumulative colloid (L)a 2.3 [1.8–2.8] 1.0 [0.8–1.5] <0.001
Cumulative colloid per weight (ml/kg)a 35.0 [27.1–44.7] 16.0 [11.0–20.1] <0.001
Packed red blood cell (unit)a 2.8 ± 2.6 2.1 ± 1.9 <0.001
Use of fresh frozen plasmaa 265 (47.8) 77 (33.6) <0.001
Use of platelet concentratea 181 (32.7) 34 (14.8) <0.001
Use of cryoprecipitatea 31 (5.6) 6 (2.6) 0.110
Weight gain (%) 1.9 ± 2.2 2.6 ± 2.1 <0.001
RPF renal protective fluid management
Data are expressed as number of patients (%), mean ± standard deviation, or median [interquartile range]
aUsed during surgery and within 48 h postoperatively
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various sensitivity analyses (Additional file 1: eTable S8).
There was a significant association between the cumula-
tive volume of HES given and the risk of developing
postoperative AKI (Additional file 1: eTable S9).
Discussion
The major finding of our present study was that the RPF
strategy was associated with a significantly lower risk of
postoperative AKI in patients who underwent OPCAB.
In addition, RPF strategy was found to be significantly
associated with a decreased incidence of severe AKI and
persistent AKI and a shorter extubation time and hos-
pital stay.
Our results indicate that a perioperative fluid manage-
ment strategy could affect renal function after OPCAB.
This finding is in accordance with previous studies in
which researchers reported an association of saline-
based solutions and unlimited amounts of HES solutions
with renal dysfunction. In recent studies, the use of bal-
anced crystalloid for replacement of fluid losses on the
day of major surgery was found to be associated with
less postoperative mortality and renal failure requiring
dialysis than normal saline [16], and implementation of
a chloride-restrictive strategy in a tertiary ICU was
found to be associated with a significantly decreased in-
cidence of AKI and use of RRT [17]. In addition, the use
of an unlimited amount of HES solution may have been
responsible for our present findings. Previous clinical
studies have suggested that HES is associated with in-
creased AKI and that higher cumulative doses of HES
are associated with greater risk of AKI development
[20, 21]. Previous retrospective studies have reported a
statistically significant dose-dependent association be-
tween intraoperative HES administration and postopera-
tive kidney injury in patients undergoing non-cardiac
surgery [19]. Additionally, moderate cumulative doses
of HES (>33 ml/kg) may be associated with a higher
risk of AKI in surgical ICU patients [22]. Our results
also show that the total median cumulative dose of
HES in the control group was 35.0 ml/kg and that
patients in the control group had a higher incidence
of AKI. These findings strongly support the notion
Table 3 Postoperative outcomes in the study groups
Control group RPF group P value
Number of patients 554 229
Acute kidney injury
RIFLE 212 (38.3) 33 (14.4) <0.001
AKIN 168 (30.3) 24 (10.5) <0.001
KDIGO 210 (37.9) 33 (14.4) <0.001
KDIGO stage ≥2 63 (11.4) 8 (3.5) <0.001
Renal replacement therapy 12 (2.2) 2 (0.9) 0.345
Persistent acute kidney injury 59 (10.7) 4 (1.7) <0.001
Extubation time (h) 10.5 [7.5–16.0] 7.5 [5.5–12.3] <0.001
Intensive care unit stay (h) 47.0 [39.8–50.5] 47.0 [42.5–49.0] 0.695
Maximal SOFA-C score 3.0 [2.0–3.0] 3.0 [0–3.0] 0.181
Hospital stay (days) 8.0 [7.0–10.0] 7.0 [7.0–9.0] <0.001
In-hospital deaths 7 (1.3) 1 (0.4) 0.512
RPF renal protective fluid management, RIFLE risk, injury, failure, loss, and
end-stage kidney disease classification, AKIN Acute Kidney Injury Network
classification, KDIGO Kidney Disease Improving Global Outcomes classification,
SOFA-C cardiovascular sequential organ failure assessment in the first 24 h
Data are expressed as number of patients (%) or median [interquartile range]
Fig. 2 Changes in serum chloride concentration before and after surgery in both groups. Data are expressed as median (interquartile range and
range). *P < 0.001 vs. preoperative value. †P < 0.001 vs. control group. RPF renal protective fluid management
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that RPF strategy is associated with a decreased inci-
dence of postoperative AKI.
In our present clinical study, we were unable to deter-
mine the mechanism by which the saline-based and HES
solutions caused an increase in AKI. A possible explan-
ation for this is provided by the renal effect of hyperchlor-
emia. Previous studies have suggested that saline-based
solutions contain a supraphysiological concentration of
chloride and that hyperchloremia caused by large-volume
administration of saline-based solutions may adversely
affect kidney function [7, 8]. Hyperchloremic acidosis is
associated with renal vasoconstriction, and, in animal
models, intrarenal infusion of chloride-rich solutions de-
creases renal blood flow and the glomerular filtration rate
[9, 10, 27]. Two earlier studies with healthy human volun-
teers found that intravenous infusion of normal saline
reduces renal blood flow velocity and renal cortical
tissue perfusion, which is not seen with use of a low-
chloride solution (Plasma-Lyte 148; Baxter Healthcare,
Old Toongabbie, Australia) [12], and that balanced starch
increases renal cortical tissue perfusion, an effect not seen
with starch in 0.9 % saline [15]. In addition, in elderly sur-
gical patients, the use of balanced crystalloid and colloid
solutions prevented the development of hyperchloremic
metabolic acidosis compared with normal saline solutions
[14]. Our results show that the preoperative serum chlor-
ide level was similar between the two study groups but
that the immediate postoperative serum chloride level was
significantly lower in the RPF group.
Another potential explanation for our present findings
could be nephrotoxicity induced by the HES solution.
HES solutions are derivatives of maize or potato starch
and can be classified according to their molecular
weight, concentration, and degree of substitution [22].
Because there is no direct chemical toxicity of HES, the
most likely mechanism for HES-induced renal dysfunc-
tion would be swelling and vacuolization of tubular cells
(“osmotic nephrosis-like lesions”) and tubular obstruction
due to the production of hyperviscous urine [28, 29]. Con-
cerns about nephrotoxicity have assumed prominence
since the introduction of HES solutions, and several clin-
ical studies have suggested that HES solutions are associ-
ated with greater incidence of renal dysfunction and RRT
[20, 30]. In line with previous studies, we found that
higher cumulative doses of HES were associated with a
greater risk of AKI development.
Another pertinent result of our present study is that
the RPF group needed less transfusion in the ICU than
the control group. This finding is in accordance with
previous reports that saline-based solutions may be asso-
ciated with coagulation abnormalities and that balanced
solutions are associated with less coagulation derange-
ment than saline-based solutions [16, 31, 32]. Although
no mechanisms have been reported for these putative
differences, it is suggested that metabolic hyperchloremic
acidosis after administration of saline-based solutions or
the small amount of calcium in the buffered electrolyte
solution might be important factors [32]. In addition, HES
infusions are known to significantly reduce factor VIII,
von Willebrand factor, and factor VIII–related ristocetin
cofactor due to dilution as well as coating of the platelet.
Consequently, there is reduced binding to the platelet
membrane receptor glycoprotein Ib (GPIb) and GPIIb/
GPIIIa and decreased platelet adhesion [33]. Investigators
in several clinical trials have reported that HES is asso-
ciated with coagulation alterations and increased blood
transfusion requirements [20, 21, 34]. Hence, the use of a
limited amount of HES would also have affected our
results.
The patients in the RPF group in our present investi-
gation had a significantly shorter extubation time and
hospital stay. Hyperchloremia in patients undergoing
non-cardiac surgery has been associated with a longer
hospital stay [11] and hyperchloremia in patients after
Table 4 Impact of renal protection fluid therapy on outcome
Unadjusted Multivariable adjusted IPTW adjusted
β (95 % CI) P value β (95 % CI) P value β (95 % CI) P value
Extubation time (h) −0.28 (−0.37, −0.18) <0.001 −0.28 (−0.37, −0.19) <0.001 −0.33 (−0.42, −0.23) <0.001
Intensive care unit stay (h) 0.02 (−0.06, 0.09) 0.682 0.03 (−0.04, 0.10) 0.400 −0.06 (−0.13, 0.02) 0.159
Hospital stay (d) −0.11 (−0.17, −0.04) 0.001 −0.11 (−0.17, −0.05) <0.001 −0.18 (−0.24, −0.11) <0.001
OR (95 % CI) P value OR (95 % CI) P value OR (95 % CI) P value
Acute kidney injury by KDIGO 0.28 (0.18–0.41) <0.001 0.31 (0.19–0.50) <0.001 0.23 (0.15–0.35) <0.001
KDIGO stage ≥2 0.28 (0.13–0.60) 0.001 0.30 (0.12–0.75) 0.009 0.12 (0.04–0.36) <0.001
Renal replacement therapy 0.40 (0.09–1.79) 0.230 – – – –
Persistent acute kidney injury 0.16 (0.06–0.45) <0.001 0.20 (0.06–0.67) 0.008 0.20 (0.08–0.52) 0.001
In-hospital death 0.34 (0.04–2.80) 0.318 – – – –
IPTW inverse probability of treatment weighting, CI confidence interval, OR odds ratio, KDIGO Kidney Disease: Improving Global Outcomes classification
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open abdominal surgery with more time requiring
mechanical ventilation [16]. Although we are unable to
explain the reasons for such associations on the basis of
our present data, previous experimental findings have
indicated that hyperchloremia can affect the immune
system, alter blood oxygen binding, and induce organ
damage [35–38]. Previous studies have also suggested
that chloride-restrictive fluid administration and a limited
use of HES were associated with a decreased requirement
for RRT and mortality [11, 16, 17, 22, 39]. However, we
did not find any significant differences in the duration of
ICU stay, incidence of RRT, or in-hospital mortality be-
tween the two groups. This may be due to a relatively
small sample size with low statistical power for identifying
their associations. In addition, the RPF group had more
positive fluid balance (represented by postoperative weight
gain in the present study) than the control group. Given
that positive fluid balance has been shown to be linked to
poor outcomes in the postoperative period of surgery [40],
it is possible that the adverse effects of positive fluid bal-
ance could counteract the beneficial effect of RPF strategy
on postoperative ICU stay, incidence of RRT, and mortal-
ity. Thus, further large studies are required to confirm the
clinical implications of our findings.
Researchers in previous studies have speculated that
positive fluid balance may affect the diagnosis of AKI
because of the dilutional effect of fluid on serum creatin-
ine [41, 42]. Thus, adjustment of creatinine for fluid bal-
ance has been proposed for a more accurate assessment
of AKI. Unfortunately, we could not calculate corrected
serum creatinine for fluid balance, as our database
contained no information on fluid output or daily
body weight. Therefore, we cannot completely exclude
the possibility that differences in fluid balance influ-
enced our results and that the beneficial effect of the
RPF strategy on postoperative renal function could be
due to unrecognized AKI as a result of the dilution
of serum creatinine by the more positive fluid bal-
ance. Further studies are warranted to assess this
issue.
To our knowledge, this is the first study of the associ-
ation between RPF strategy and postoperative AKI in
cardiac surgery patients. Previous clinical studies have
reported that balanced solutions are associated with re-
duced incidence of postoperative AKI, but few studies
have assessed the impact of balanced solutions, includ-
ing both crystalloids and colloids, on postoperative AKI.
In one previous study [17], patients received intravenous
fluids with crystalloids and colloids, but these colloids
included 4 % succinylated gelatin solution, 4 % albumin
in sodium chloride, and 20 % albumin solution and did
not include HES. In another study [14], the use of bal-
anced crystalloid and colloid solutions in elderly patients
was found to reduce hyperchloremic metabolic acidosis
compared with saline-based solutions, but that report
did not include an assessment of the effect of bal-
anced solutions on AKI. In our present analyses, pa-
tients received intravenous fluids with crystalloid and
HES. Hence, we present the first study assessing the
impact of balanced solutions with crystalloid and HES
on postoperative AKI in patients who underwent
OPCAB. Our findings might therefore suggest a peri-
operative fluid management strategy that could im-
prove the outcome of patients who undergo cardiac
surgery.
Our study has several limitations. First, the two study
groups were from different time periods, raising the pos-
sibility of related confounding factors. For example,
growing concerns about AKI might have encouraged
anesthesiologists to implement interventions and anes-
thetics for the RPF group, resulting in better outcomes.
Furthermore, although we performed multivariable re-
gression and propensity analyses in an attempt to control
bias, the limitations of a non-randomized observational
study remain. Because unmeasured variables cannot be
controlled by the statistical models presented, it is still
possible that residual confounding influenced the results.
In other words, it is possible that any differences in renal
outcomes between the two groups could be due to un-
measured severity-of-illness differences. Therefore, despite
the strong associations between the perioperative RPF
strategy and post-OPCAB AKI, given the retrospective ob-
servational nature of our analysis, causality could not be
determined, and our findings should be considered as
hypothesis-generating. Further prospective randomized
studies are required to advance understanding of this rela-
tionship. Finally, the RPF strategy we used included two
different factors: use of balanced solutions and use of a
limited amount of colloid solution. We were unable to de-
termine which had more of an impact on our results.
However, our findings indicated that these two factors
of the RPF strategy were significantly associated with
a decreased incidence of postoperative AKI. Accord-
ingly, our present results should be interpreted with
caution, and further randomized controlled studies
are needed.
Conclusions
There is a statistically significant and clinically important
association between RPF strategy and postoperative AKI
in patients undergoing OPCAB. The RPF strategy is
associated with a significantly decreased incidence of
severe AKI and persistent AKI and a shorter extubation
time and hospital stay. The RPF strategy thus appears to
improve outcomes in patients undergoing OPCAB and,
when used in a perioperative fluid management strategy,
can be recommended in patients who show evidence of
early AKI or are at risk of AKI.
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Key messages
 Perioperative fluid management strategy could affect
postoperative renal function and clinical outcomes.
 The use of balanced solutions and a limited volume
of HES solution may have beneficial effects on renal
function and other clinical outcomes in patients
undergoing off-pump coronary artery bypass graft
surgery.
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